These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

974 related articles for article (PubMed ID: 27118149)

  • 1. Risk and predictors of hepatocellular carcinoma for chronic hepatitis B patients with newly developed cirrhosis.
    Chien J; Liu J; Lee MH; Jen CL; Batrla-Utermann R; Lu SN; Wang LY; You SL; Yang HI; Chen CJ
    J Gastroenterol Hepatol; 2016 Dec; 31(12):1971-1977. PubMed ID: 27118149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Natural history of chronic hepatitis B REVEALed.
    Chen CJ; Yang HI
    J Gastroenterol Hepatol; 2011 Apr; 26(4):628-38. PubMed ID: 21323729
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction models of long-term cirrhosis and hepatocellular carcinoma risk in chronic hepatitis B patients: risk scores integrating host and virus profiles.
    Lee MH; Yang HI; Liu J; Batrla-Utermann R; Jen CL; Iloeje UH; Lu SN; You SL; Wang LY; Chen CJ;
    Hepatology; 2013 Aug; 58(2):546-54. PubMed ID: 23504622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in serum levels of HBV DNA and alanine aminotransferase determine risk for hepatocellular carcinoma.
    Chen CF; Lee WC; Yang HI; Chang HC; Jen CL; Iloeje UH; Su J; Hsiao CK; Wang LY; You SL; Lu SN; Chen CJ;
    Gastroenterology; 2011 Oct; 141(4):1240-8, 1248.e1-2. PubMed ID: 21703214
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-invasive tests for liver disease severity and the hepatocellular carcinoma risk in chronic hepatitis B patients with low-level viremia.
    Paik N; Sinn DH; Lee JH; Oh IS; Kim JH; Kang W; Gwak GY; Paik YH; Choi MS; Lee JH; Koh KC; Paik SW
    Liver Int; 2018 Jan; 38(1):68-75. PubMed ID: 28581248
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new laboratory-based algorithm to predict development of hepatocellular carcinoma in patients with hepatitis C and cirrhosis.
    El-Serag HB; Kanwal F; Davila JA; Kramer J; Richardson P
    Gastroenterology; 2014 May; 146(5):1249-55.e1. PubMed ID: 24462733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Determinants of spontaneous surface antigen loss in hepatitis B e antigen-negative patients with a low viral load.
    Tseng TC; Liu CJ; Yang HC; Su TH; Wang CC; Chen CL; Kuo SF; Liu CH; Chen PJ; Chen DS; Kao JH
    Hepatology; 2012 Jan; 55(1):68-76. PubMed ID: 21858846
    [TBL] [Abstract][Full Text] [Related]  

  • 8. What can we learn from hepatitis B virus clinical cohorts?
    Lin CL; Tseng TC; Kao JH
    Liver Int; 2015 Jan; 35 Suppl 1():91-9. PubMed ID: 25529093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perspectives and control of hepatitis B virus infection in Taiwan.
    Lin CL; Kao JH
    J Formos Med Assoc; 2015 Oct; 114(10):901-9. PubMed ID: 26184565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid Alanine Aminotransferase Normalization with Entecavir and Hepatocellular Carcinoma in Hepatitis B Virus-Associated Cirrhosis.
    Kim EJ; Yeon JE; Kwon OS; Lee HN; Shin SK; Kang SH; Byun KS; Kim JH; Kwon SY; Suh SJ; Yim HJ; Kim YS; Kim JH
    Dig Dis Sci; 2017 Mar; 62(3):808-816. PubMed ID: 28035553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rates of cirrhosis and hepatocellular carcinoma in chronic hepatitis B and the role of surveillance: a 10-year follow-up of 673 patients.
    Poh Z; Goh BB; Chang PE; Tan CK
    Eur J Gastroenterol Hepatol; 2015 Jun; 27(6):638-43. PubMed ID: 25831135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term outcomes and predictive scores for hepatocellular carcinoma and hepatitis B surface antigen seroclearance after hepatitis B e-antigen seroclearance.
    Fung J; Cheung KS; Wong DK; Mak LY; To WP; Seto WK; Lai CL; Yuen MF
    Hepatology; 2018 Aug; 68(2):462-472. PubMed ID: 29534307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus infection and hepatocellular carcinoma among parous Taiwanese women: nationwide cohort study.
    Fwu CW; Chien YC; Kirk GD; Nelson KE; You SL; Kuo HS; Feinleib M; Chen CJ
    J Natl Cancer Inst; 2009 Jul; 101(14):1019-27. PubMed ID: 19535774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rate of incidence of hepatocellular carcinoma in patients with compensated viral cirrhosis.
    Chiaramonte M; Stroffolini T; Vian A; Stazi MA; Floreani A; Lorenzoni U; Lobello S; Farinati F; Naccarato R
    Cancer; 1999 May; 85(10):2132-7. PubMed ID: 10326690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of hepatocellular carcinoma in HBV cirrhotic patients assessed by the combination of miR-122, AFP and PIVKA-II.
    Caviglia GP; Abate ML; Gaia S; Petrini E; Bosco C; Olivero A; Rosso C; Ciancio A; Pellicano R; Saracco GM; Rizzetto M; Smedile A
    Panminerva Med; 2017 Dec; 59(4):283-289. PubMed ID: 28650134
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
    Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
    Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
    Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
    Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The discrepancy of HBsAg titre and HBV DNA in patients with chronic hepatitis B, HBV-related liver cirrhosis and hepatocellular carcinoma].
    Pei YZ; Han T; Ma XY; Li Y; Xing J; Song ZL
    Zhonghua Gan Zang Bing Za Zhi; 2011 Oct; 19(10):743-6. PubMed ID: 22409845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rs2296651 (S267F) variant on NTCP (SLC10A1) is inversely associated with chronic hepatitis B and progression to cirrhosis and hepatocellular carcinoma in patients with chronic hepatitis B.
    Hu HH; Liu J; Lin YL; Luo WS; Chu YJ; Chang CL; Jen CL; Lee MH; Lu SN; Wang LY; You SL; Yang HI; Chen CJ;
    Gut; 2016 Sep; 65(9):1514-21. PubMed ID: 26642861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics of elderly hepatitis C virus-associated hepatocellular carcinoma patients.
    Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Tada T; Tanaka J
    J Gastroenterol Hepatol; 2013 Feb; 28(2):357-64. PubMed ID: 23190084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 49.